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EFFECT OF DELAYS ON SURVIVAL IN PATIENTS WITH 
LUNG CARCINOMA IN MONTENEGRO
Danko Živković
Brezovik Special Hospital for Lung Diseases and Tuberculosis, Medical Faculty of Podgorica, Nikšić, 
Montenegro
SUMMARY – Lung cancer is a global medical problem with a rising incidence and 5-year 
survival of 5%-10%. The aim of this study was to investigate whether waiting times and delays in 
diagnosis and treatment of patients with lung carcinoma have any bearing on prognosis and survi-
val. The study was performed in the Brezovik Special Hospital for Lung Diseases and Tuberculosis. 
The study included all cases with the diagnosis of lung carcinoma in the Republic of Montenegro 
in 2009, a total of 206 patients, with follow up until the end of 2010. Median age was 66, median 
Karnofsky score 80, and male to female ratio 5:1. Diagnostic procedure was bronchoscopy in 89% of 
patients. Histologic type was small cell lung cancer in 25.7% and non small cell lung cancer in 74.3% 
of cases. Surgery was the main treatment for 24.4% of patients. Median delay from first symptoms 
to diagnosis of lung cancer was 10.35 weeks, mean 8 weeks (median patient’s delay was 6.20 weeks, 
doctor’s delay at primary health care 2.07 weeks and in pulmonology services 2.37 weeks). Median 
survival time for all patients was 39.27 weeks, mean 34. There was no statistically significant diffe-
rence between patient’s delay/doctor’s delay/total delay and stage of lung carcinoma at the time of 
diagnosis, treatment choice and survival. Our results indicate that longer delay is not associated with 
poorer prognosis of lung carcinoma. The possible ways of reducing mortality of lung cancer include 
prevention by decreasing smoking prevalence and improved therapeutic options. 
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Introduction 
Lung cancer is one of the most common cancers 
and has poor prognosis. Worldwide, an estimated 1.7 
million of new cases of lung cancer were expected to 
be diagnosed in 2010, accounting for approximately 
13 percent of total cancer diagnoses. Lung cancers are 
the leading cause of cancer death worldwide, with an 
estimated 1.4 million deaths each year. In Europe, 
lung cancer accounts for 20 percent of an estimate 
(over 350,000) of all cancer-related deaths in Europe, 
the highest of any cancer1. The decrease in the inci-
dence rates of squamous cell carcinoma and small cell 
lung carcinoma (SCLC) among men was probably 
due to a decrease in the percentage of smokers. The in-
crease in adenocarcinoma has also been described and 
in the USA adenocarcinoma is now even the leading 
lung cancer cell type2. Despite recent advances in the 
treatment, prognosis for patients with lung carcinoma 
remains poor; the 5-year survival rate for patients with 
non small lung cell carcinoma (NSCLC) is still only 
about 15% in Europe3. 
According to the available data, the lung carci-
noma incidence rate in Montenegro showed a steady 
growth between 1978 and 2005, with an average an-
nual increase of 6%. In male population, the incidence 
rate rose from 19.6/100,000 to 48.5/100,000, with a 
mean annual growth of 5.8%. The mean standardized 
incidence rate was 39.2/100,000 in male population. 
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Between 1976 and 2005, the lung cancer mortality rate 
in Montenegro increased from 19.4 to 26.3/100,000, 
with an average growth rate of 2%. According to our 
statistics, around 300 Montenegro citizens are diag-
nosed with this disease every year.
Nowadays, the importance of ‘time factor’ in the 
diagnosis of lung cancer is examined through new 
medical methods. In this respect, ‘patient’s delay’ and/
or ‘health care delay’ are evaluated separately. In case 
of lung carcinoma, the effect of ‘delay’ on survival re-
mains a great mystery. Previous studies suggest that 
both the diagnosis and the initiation of treatment 
should be done as early as possible4. Treatment delays 
are a constant problem. According to some studies, 
delay has a negative impact on the prognosis, while 
other did not show such a correlation4-7.
Time intervals between the onset of symptoms 
and diagnosis and beginning of treatment of a patient 
could be divided into ‘patient’s delay’ and ‘doctor’s de-
lay’. Patient’s delay is the time between the first symp-
toms and the first contact with medical workers. Doc-
tor’s delay is defined as a time interval between the 
first examination at a health care institution and the 
beginning of treatment or a decision that the cancer 
specific treatment is not possible8. 
According to the research conducted by Moore et 
al. in the United States of America, a delay of over 
three months was observed in 25% of patients. The 
longest delay, four months on average, was noticed 
in the studies including patients aged <45 from the 
USA9. There are great variations in the intervals be-
tween the first contact with doctor and the established 
diagnosis. According to the Swedish study by Chris-
tensen et al.9, the first doctor’s delay was seen at the 
level of general practitioners and it amounted to 56 
days. 
The study by Billing and Wells15 define total delay 
as a period between the first visit to the general prac-
titioner and surgery, giving further divisions into sub-
groups according to the reasons for delay. According 
to the study by Christensen et al., the end-point is the 
date when a patient is either operated on or considered 
inoperable9. 
The tumor could spread considerably during the 
delay time. It is considered that tumor growth from 
Tx to T1, T2 is not just a local growth of the tumor 
but also an increase in its metastatic potential, mean-
ing that there is more chance that N increases with 
an increase of T, the same as M0 in M1. In the study 
by O’Rourke and Edwards12, the NSCLC patients re-
ferred for radiotherapy initially had a diagnostic com-
puted tomography (CT) scan and later a radiotherapy 
planning CT scan. Delay between the two CT scans 
amounted to 18-131 days (median 54 days) and tumor 
growth in terms of percentage change in tumor cross-
sectional area ranged from 0 to 373%, with a median 
increase of 19% in the time elapsed12. The studies by 
Porta et al. focused on the association between delay 
and survival. According to this study, a significantly 
better rate of survival was found in patients with lon-
ger patient’s delay than in those with longer doctor’s 
delay13,14. The study by Alberts et al. examined the 
causes of unnecessary doctor’s delay15-17. According to 
them, one of the major reasons is the lack of compre-
hensive multidisciplinary approach to the treatment 
of patients with lung carcinoma. 
Recommendations of the British Thoracic Society 
on the time intervals for evaluation, diagnosis and 
treatment are aimed at providing guidelines and good 
practice for treating a patient with lung carcinoma18,19. 
According to these guidelines: 1) all patients should 
be examined no longer than one week from referral by 
the home doctor; 2) diagnostic workup must be com-
pleted no later than two weeks from the date when 
lung carcinoma was suspected; 3) chemotherapy must 
start no longer than seven days of the council’s deci-
sion on the type of treatment; 4) radiotherapy should 
start no longer than two weeks after the decision has 
been made for urgent cases, and no longer than four 
weeks after the decision has been made for compli-
cated cases, while waiting time for palliative radio-
therapy should be no longer than two weeks; and 5) 
surgical intervention (operation) should be completed 
within four to eight weeks after the treatment deci-
sion has been made20.
Objective of the study 
The main contribution of this study is to examine 
the correlation of delay and survival in patients with 
lung carcinoma. The hypothesis for this carcinoma 
localization is that the delay factor has a limited sig-
nificance, i.e. it has no bearing on the lung carcinoma 
mortality. The research is expected to provide answers 
to the following questions:
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•	 Do patient’s delay and/or doctor’s delay, as well as 
the total delay have any bearing on the length of 
survival in lung cancer patients? 
•	 What is the real prognostic significance of delay 
for lung cancer?
•	 What recommendations could be issued in order to 
improve the outcome of treatment of lung cancer 
patients, what level should the efforts be focused 
on in order to raise the awareness of patients and 
society, and to improve coordination within health 
service?
Materials and Methods
The subject of the research was the effect of delay 
on the lung carcinoma prognosis, focusing on the total 
delay, patient’s delay, and health service delay, includ-
ing relations between the doctors of primary health 
care and specialist service, as well as the time interval 
from diagnosis to the beginning of any type of treat-
ment of the primary malignant process in the lungs. 
At the Brezovik Special Hospital for Lung Diseases 
and Tuberculosis, the institution in charge of lung car-
cinoma diagnosis and treatment at the national level, 
approximately 200-250 new lung carcinoma patients 
are diagnosed every year. In the last several years, this 
number has seen a steady growth. 
This retrospective study included all lung carcino-
ma patients hospitalized at the Brezovik Special Hos-
pital for Lung Diseases and Tuberculosis in Nikšić 
over a 12-month period (2009), with 12-month follow 
up after inclusion of the last patient in the study. The 
study included a total of 206 lung carcinoma patients, 
who were diagnosed and treated between January 1 
and December 31, 2009, and monitored for the next 
12 months until the end of 2010.  
We analyzed patient survival in relation to delay 
between the onset of first symptoms and the diagno-
sis, patient’s and doctor’s delay. Study patients were 
divided into two groups: patients diagnosed within 
eight weeks and patients diagnosed beyond eight 
weeks of the onset of first symptoms. 
We performed Kaplan-Meier analysis of survival 
for the group of surveyed patients in relation to the 
period between the onset of first symptoms and the 
end of the study.
Results 
In compliance with the methodology used, our 
study included 206 patients, diagnosed and treated in 
2009 at the Brezovik Special Hospital for Lung Dis-
eases and Tuberculosis in Nikšić, Montenegro. Lung 
carcinoma is a disease of middle-aged men, with a 
peak incidence in the seventh decade of life. In the last 
two decades, a sudden growth was seen in the number 
of female lung carcinoma patients, associated with an 
increase in the number of female smokers. Accord-
ing to gender analysis, most of the patients included 
in our study were men (n=171, 83.0%), while only 35 
(17.0%) were women, yielding a male to female ratio 
of 5:1.
Having analyzed the group of patients according 
to their smoking habits, we concluded that out of 206 
patients, 167 (81%) were smokers, 75% of them heavy 
smokers (140/206). The mean length of smoking his-
tory was 29.4 years, with a mean of 29.17 cigarettes 
daily.
Patient’s delay
Conducting patient survey concerning the time 
elapsed between the onset and recognition of first 
symptoms of the disease and their consultations with 
doctors (patient’s delay), we found that this time in-
terval ranged from 2-3 days to 33 weeks, mean 6.2 
weeks (range, 0.23-33.00 weeks, 95% confidence in-
terval (95% CI) for 206 patients) or median of 4.00 
weeks (95% CI). Medical records and patient inter-
views revealed that a mean of 6.52 weeks had elapsed 
between the onset of first symptoms and chest radiog-
raphy (between 1.00 and 34.00 weeks with 95% CI). 
Doctor’s delay I
The mean doctor’s delay in primary health care un-
til examination by a lung disease specialist was 2.07 
weeks (between 1.00 and 20.00 weeks with 95% CI). 
The Brezovik Special Hospital for Lung Diseases is a 
central institution for diagnosis and treatment of lung 
carcinoma in Montenegro, which means that almost 
all patients were treated there. Decisions on the man-
ner of treatment of lung cancer patients are made by a 
council. In most cases, histopathologic findings were 
obtained after bronchoscopy. In few patients, ma-
lignant lung disease was diagnosed after the surgery 
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(video-assisted thoracoscopic surgery (VATS) wedge 
resection) performed at the Department of Chest 
Surgery, Clinical Center of Montenegro in Podgorica. 
The mean delay of the specialist medical service was 
2.37 weeks. 
Doctor’s delay II 
Having added together primary health care doc-
tor’s delay (I) and specialist medical service delay (II) 
before primary lung carcinoma was diagnosed, we 
concluded that the health care delay or total doctors’ 
delay was 4.22 weeks (between 1.00 and 23.00 weeks 
with 95% CI). 
Total delay 
Adding together patient’s delay and health care 
delay yielded a mean total delay of 10.35 weeks. For 
the whole group of 206 patients surveyed, median 
delay was 8.0 weeks (between 2.00 and 51.00 weeks 
with 95% CI).
According to statistical analysis based on the Ka-
plan-Meier method, it is evident that the cumulative 
survival was 12 weeks after the onset of first symp-
toms with 95% CI. The mean survival time was 44.17 
weeks, between 40.66 and 47.68 weeks with 95% CI. 
Median survival was 39 weeks, between 34.32 and 
43.68 weeks, with 95% CI (Fig. 1).
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According to statistical analysis based on the Ka-
plan-Meier method, the mean survival after the diag-
nosis was 35.48 weeks, between 31.94 and 39.02 weeks 
with 95% CI. Median survival was 28 weeks, between 
24.02 and 31.98 weeks, with 95% CI (Fig. 2).
Survival in relation to patient’s delay under and over 8 
weeks
In compliance with the task of the study, we di-
vided our patients into two groups: patients having 
recognized their symptoms and consulting doctors 
within 8 weeks and patients with a delay longer than 
8 weeks, and analyzed their survival.
The group of patients with a delay shorter than 8 
weeks included 104 of 206 patients. Median survival 
in the group with shorter delay was 35.00 weeks (95% 
CI: 29.86-40.16), while median survival in the group 
of patients that had recognized their symptoms and 
consulted doctors after 8 weeks was 40.00 (95% CI: 
33.07-46.93). There was no statistically significant 
between-group difference in survival according to pa-
tient’s delay (p>0.05) under and over 8 weeks.
The group of patients diagnosed within 8 weeks in-
cluded 30 of 104 live patients. Median survival in the 
group of patients diagnosed within 8 weeks was 30.00 
weeks (95% CI: 24.82-35.18), while median survival 
in the group of patients diagnosed after 8 weeks was 
27.00 (95% CI: 20.44-33.56). There was no statisti-
cally significant between-group difference in survival 
according to patient’s delay (p>0.05) under and over 8 
weeks (Fig. 3).
According to study results, the most common type 
of NSCLC was squamous cell carcinoma found in 
46.1%, whereas SCLC was found in 55 (26.7%) pa-
tients (Table 1). 
In our study, survival of the SCLC patients ranged 
between 33.83 and 47.26 weeks after the onset of first 
symptoms, with median survival of 32.00 weeks. In 
the group of NSCLC patients, survival ranged be-
tween 41.31 and 49.47 weeks, with median survival of 
40.00 weeks for the log rank 1.16 and p=0.2810 (Fig. 
4). There was no statistically significant difference in 
survival according to histopathologic type of the dis-
ease (p>0.05).
In our study, survival of SCLC patients ranged 
between 25.73 and 37.88 weeks, with median sur-
vival of 25 weeks. In the group 
of NSCLC patients, survival 
ranged between 32.52 and 
40.987 weeks, with median 
survival of 30.00 weeks for the 
log rank 1.42 and p=0.2334.
There was no statistically 
significant difference in sur-
vival after disease diagnosis ac-
cording to histopathologic type 
of the disease (Mann-Whitney 
test u=3.667; z=0.972; p>0.05).
Table 1. Patient distribution according to histologic types of lung cancer
Histologic type of lung cancer Number of patients % Total %
SCLC, small cell lung carcinoma 55 25.7 25.7
NSCLC, squamous cell lung carcinoma 93 46.1 71.8
NSCLC, adenocarcinoma 26 12.6 84.5
NSCLC, miscellaneous type 5 2.4 86.9
NSCLC, large cell carcinoma 27 13.1 100.0
Total 206 100.0 100.0
NSCLC = non small cell lung carcinoma
Fig. 4. Survival curve after the onset of first symptoms 
in relation to histopathologic type: small cell lung carci-
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Discussion 
In the literature, the effect of delay on survival of 
lung carcinoma patients has been defined as unpredict-
able. Most of the studies started from an assumption 
that shorter delay results in better survival rate. How-
ever, some research results did not confirm this assump-
tion. The results of the study by Myrdal et al.10 show 
that not even longer patient’s delay and longer doctor’s 
delay were associated with worse prognosis and shorter 
survival. On the contrary, the prognoses were worse in 
patients with shorter delay. Moreover, the results of this 
study showed that patients with limited disease had 
longer delay until they received cancer specific treat-
ment than those with advanced disease. 
According to the observations reported by Salomaa 
et al.21, the growth of NSCLC is based on mathemati-
cal models, suggesting that it takes 10 to 15 years from 
the appearance of the first cancer cells to the possibil-
ity of detecting NSCLC by conventional chest radio-
graph. According to the literature, the time observed 
for lung tumors to double their volume ranges from 
4 to 56 weeks, with median time of 17 weeks. This 
indicates that the growth of a tumor is comparatively 
slow22,23. Two studies monitored the growth of prima-
ry tumor with consequent CT chest scans, observing 
great diversity in the time of tumor growth15,24. The 
previous studies have failed to answer the question 
when the metastasis of lung carcinoma starts25. Ac-
cording to the study by Jung et al., in patients with 
T1 lung carcinoma, extra-pulmonary metastases were 
found in 13% of patients at diagnosis, while distant 
metastases were found in 24% of patients one year 
later26. If metastases have started growing years before 
the lung carcinoma is detected, it is difficult to expect 
that the delay will have any prognostic significance27. 
The age and gender distribution of patients in our 
study was consistent with that in other studies. Our 
patients were of similar age, median 66, compared 
with median 65 in the American and 68 in Western 
European studies23. The female to male ratio of the 
disease is 1:3-4 on the American continent, while in 
our study it was 1:5. If the number of women with 
lung carcinoma continues to grow, it is expected that 
the lung carcinoma incidence in women will have ex-
ceeded the one in men by 20302. 
Having analyzed patient’s delay, our study showed 
the mean delay between the onset and recognition of 
first symptoms and presentation to doctor to be 6.2 
weeks (95% CI 0.23-33.0). The delay between the on-
set of first symptoms and the beginning of treatment 
was 9.63 weeks (95% CI: 1-35.0). 
Correlating patient’s delay with the histologic type 
of lung carcinoma yielded no statistical significance, as 
it was 10.6 weeks in SCLC patients and 12.00 weeks 
in NSCLC patients (153/206). 
In comparison with the results of the Italian re-
searchers presented in the G.I.V.I.O. study28, which 
reported a mean delay of 7 days, our research indi-
cated a little longer delay, but it could be considered 
as a comparatively short delay in general, in com-
parison with the results reported by Myrdal et al.10 
on 4.6-month delay, or by Mood et al.29, who found 
a delay longer than 3 months in 25% of patients. The 
longest patient’s delay was observed in the studies in-
cluding the U.S. patients aged under 45, amounting to 
an average of 6 months. 
Mackillop et al.30 explain such a wide range of pa-
tients’ delay by cultural and economic conditions in 
the places of research, as well as by the education level 
of the population surveyed. 
In their study, Bowen and Razner31 say that pa-
tient’s delay is longer in men. Myrdal et al.10 argue that 
the delay from symptoms to treatment is shorter in 
patients with stage IV lung carcinoma (median 3.4 
months) than in stage I and II patients (median 5.5 
months). They explain it by the fact that patients with 
advanced disease have more disease symptoms and 
signs making them to contact a doctor. 
In Canada, it is recommended that the interval 
between the examination by a selected doctor and di-
agnosis should be maximum 4 weeks, while the one 
between the diagnosis and surgery should be no lon-
ger than two weeks32. According to the retrospective 
study by Myrdal et al.10 , doctor’s delay in one half of 
the NSCLC patients amounted to 2.5 months. The 
cancer specific treatment started within 6 weeks from 
the first consultation with a chest physician. Surgi-
cally treated patients had longer delay than those who 
did not undergo surgery. According to the study by 
Deegan et al., median doctor’s delay was reduced to 
five weeks after the first consultation with a doctor27.
In our study, doctor’s delay included primary health 
care delay and secondary, i.e. tertiary health service de-
lay (specialist services). In our case, primary health care 
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delay was 2.07 weeks (95% CI: 1.0-20.0) and special-
ist services’ delay was similar, 2.37 weeks. Total delay 
amounted to 4.22 weeks (95% CI: 1.00-23.00). 
Comparing the results of our study with those 
from the literature, it is concluded that doctor’s delay 
was considerably shorter in our study. The reason for 
this could be sought in the centralization of health 
care in Montenegro and the role of councils in decid-
ing on the treatment of patients with lung carcinoma.
The main parameter of success in the treatment 
of patients with malignant disease is survival. There 
was no statistically significant difference in patient 
survival after the onset of first symptoms according 
to the histologic type of lung carcinoma (p>0.05), or 
according to the time of malignant disease diagnosis 
(p>0.05). Analysis of survival according to patient’s 
delay shorter than eight weeks (shorter delay) and lon-
ger than eight weeks (longer delay) yielded no statisti-
cally significant difference (p>0.05). Namely, median 
survival was 35.00 weeks (95% CI: 29.86-40.16) in 
the group with shorter delay and 40.00 (95%: 33.07-
46.93) in the group with longer delay. Comparison of 
patient survival according to the time of lung carcino-
ma diagnosis using the same parameters (delay shorter 
and longer than eight weeks) showed no statistically 
significant difference either (p>0.05). Our results are 
consistent with those reported by Aragoneses et al.33. 
They did not observe any statistically significant dif-
ference in survival according to the lung carcinoma 
histology, clinical stage, and length of delay in any pe-
riod, even when patients with the shortest delay of 1 
to 20 days were compared with those with the longest 
delay of over 60 days. 
We compared survival of SCLC-limited stage dis-
ease (LD) patients with a group of SCLC-extensive 
stage disease (ED) patients from the onset of first 
symptoms and found a statistically significant dif-
ference in survival (p<0.001). Median survival was 
48 weeks (95% CI: 22.27-73.73) in the group with 
SCLC-LD and 30.00 weeks (95% CI: 24.44-35.56) 
in the group with SCLC-ED. There was a statistically 
significant difference (p<0.004) in survival of patients 
with SCLC from diagnosis according to the stage of 
disease. Median survival of patients with limited dis-
ease was 40 weeks (95% CI: 29.07-50.93), while me-
dian survival of those with advanced stage disease was 
18 weeks (95% CI: 15.77-20.23). 
Having analyzed survival of patients with NSCLC 
from the onset of first symptoms, we found longest 
survival in patients with stage I disease, who were all 
alive when the study was completed. Median survival 
was 88.00 weeks in stage II NSCLC patients, 62.00 
weeks in stage IIIa patients, 37.00 weeks in stage IIIb 
patients, and 26.00 weeks in patients with stage IV 
NSCLC. 
There was no significant difference in survival 
between patients with stage I and stage II NSCLC 
according to delay from the onset of first symptoms. 
A difference in survival was found in patients with 
stage I and II disease as compared with those with 
advanced stage IIIb and IV according to delay from 
the onset of first symptoms. 
Analysis of survival in patients with NSCLC ac-
cording to delay from diagnosis yielded a statistically 
significant difference between stage I-II patients and 
patients with advanced stage III b and IV disease. In 
compliance with the defined objectives, we analyzed 
survival of patients in relation to metastasis. Metas-
tases were found in 32.5% of patients. The most fre-
quent localization of metastases was the liver (22.5%). 
There was a high statistically significant difference in 
survival both from the onset of first symptoms and 
from diagnosis according to the presence of metasta-
ses (p<0.005). 
The main limitations of this study were the retro-
spective type of the study and the number of patients 
included in the study. The number of study patients 
was not big enough to make strong conclusions from 
the results of statistical analysis. The number of pa-
tients probably determined great variations in statisti-
cal analysis and the results obtained. That is the reason 
why we did not get statistical significance in examined 
delays and survival of patients with lung carcinoma. 
The specificity of the study population lies in its 
structure, also in a centralized and accessible specialist 
care (all patients were treated at the same institution). 
Unlike all younger age structures, increasing the propor-
tion of women among patients and the predominance 
of adenocarcinoma in most developed countries of the 
West, the Montenegrin population consists mainly of 
older men with a high risk of cigarette smoking and the 
most common diagnosis of squamous cell carcinoma, 
stage III and IV disease. These results represent the 
current situation with lung carcinoma in Montenegro 
Acta Clin Croat,  Vol. 53,   No. 4,  2014 397
D. Živković Effect of delays on survival in patients with lung carcinoma in Montenegro
and could be useful for further steps in making health 
care decisions and strategies. 
Conclusion
Our study included 206 patients diagnosed with 
malignant lung carcinoma in 2009. It included all 
lung carcinoma patients in Montenegro that year. Ac-
cording to our research, lung carcinoma is a disease of 
middle-aged men, with a peak incidence in the sev-
enth decade of life, most frequently found in heavy 
smokers. According to gender structure, 83% of pa-
tients were men and 17% women, yielding a 5:1 male 
to female ratio. Ten percent of patients were younger 
than 50, while 20% were aged over 70.  
The main parameter of success in the treatment of 
patients with malignant disease is survival. There was 
no statistically significant difference in survival accord-
ing to patient’s or doctor’s delay (p>0.05), probably due 
to the limitations of the study such as retrospective de-
sign and small number of patients. On the other hand, 
these results represent current situation of the specific 
Montenegrin population with lung carcinoma. 
Lung carcinoma is still a great medical challenge 
all over the world. In view of the research conducted 
so far, there are four possible ways to reduce the re-
spective death rate:
– prevention (reduction) of smoking;
– early diagnosis by means of new screening tech-
nologies; 
– appropriate approach to patients in a more efficient 
health system; and
– improvement of treatment options. 
Fatalistic attitude of doctors towards this disease 
has changed and great efforts and funding are now in-
vested in clinical practice in order to improve diagnos-
tic procedures for this disease. These efforts are in part 
focused on the reduction of health service delay. Bet-
ter coordination among doctors and team approach to 
treatment are the basis for a more efficient treatment 
of patients with lung carcinoma. If time intervals are 
reduced to minimum, the possibility of early detection 
of this disease will be higher, as well as the chances to 
‘prolong’ survival of these patients. 
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Sažetak
UČINAK zAKAŠNJELE DIJAGNOzE NA PREŽIVLJENJE KOD BOLESNIKA S PLUĆNIM TUMORIMA 
U CRNOJ GORI
D. Živković
Karcinom pluća je globalni medicinski problem s rastućom incidencijom i 5-godišnjim preživljavanjem od 5%-10%. 
Cilj ovoga rada bio je istražiti utječe li izgubljeno vrijeme (kašnjenje) u dijagnozi i liječenju bolesnika s karcinomom plu-
ća na prognozu i preživljavanje oboljelih. Istraživanje je provedeno u Specijalnoj bolnici za plućne bolesti i tuberkulozu 
Brezovik. U studiju su bili uključeni svi slučajevi s dijagnozom raka pluća u 2009. godini u Republici Crnoj Gori, ukupno 
206 bolesnika, s praćenjem do kraja 2010. godine. Srednja životna dob je bila 66 godina, srednji Karnofski skor 80, od-
nos prema spolu 5 M:1 Ž. Histološki tip je bio mikrocelularni karcinom (SCLC) u 25,7% i nemikrocelularni karcinom 
(NSCLC) u 74,3% slučajeva. Kirurgija je bila osnovno liječenje za 24,4% bolesnika. Srednje “izgubljeno vrijeme” od prvih 
simptoma bolesti do dijagnoze raka pluća je bilo 10,35 tjedana, medijan 8 tjedana (srednje izgubljeno vrijeme bolesnika 
je bilo 6,20 tjedana, liječnika u primarnoj zdravstvenoj zaštiti  2,07 tjedana i liječnika pulmologa 2,37 tjedana). Srednje 
vrijeme preživljavanja za sve bolesnike je bilo 39,27 tjedana, medijan 34. Nije nađena statistički značajna razlika između 
izgubljenog vremena bolesnika, liječnika i ukupno izgubljenog vremena u odnosu na stadij bolesti u trenutku postavljanja 
dijagnoze, terapijski izbor i preživljavanje bolesnika. Naši rezultati ukazuju na to da duže izgubljeno vrijeme nije praćeno 
lošijom prognozom karcinoma pluća. Mogući putovi u smanjenju smrtnosti od raka pluća su prevencija borbom protiv 
pušenja i  poboljšanje terapijskih mogućnosti.   
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